In order to evaluate the significance of epidermal cell proliferation for the first stage of skin tumor promotion, the effect of hydroxyurea (HU), an inhibitor of DNA synthesis, on tumor formation was studied. Mice initiated with 7,12-dimethylbenz [a]anthracene received a single dose of phorbol 12-myristate 13-acetate (PMA) in stage I of promotion, followed by twice weekly application of the irritant skin mitogen phorbol 12-retinoate 13-acetate in stage II. A An induction of hyperproliferation and perhaps inflammation are probably necessary, but certainly not sufficient, conditions of promotion because irritant skip mitogens have been described (3-5) that are highly effective in these respects but almost completely lack promoting capacity. Therefore, a tumor promoter must have an additional activity. Most of the biochemical responses of mouse skin to application of promoters such as phorbol ester PMA (phorbol 12-myristate 13-acetate) analyzed so far seem to be related to hyperproliferation and inflammation (3, 6) but do not shed light on the nature of the particular mechanisms involved in promotion. Recently, skin tumor promotion has been found to consist of two different stages (3, 7, 8) . Whereas for stage I a single (i.e., subthreshold) application of a promoter such as PMA is sufficient, stage II is performed by continuous treatment with an "incomplete" promoter (3, 7). Incomplete promoters such as phorbol 12-tetradeca-2,4,6,8-tetraenoate 13-acetate (Ti8) and phorbol 12-retinoate 13-acetate (PRA) (3, 6) exhibit hyperplasiogenic and irritant activities like those of PMA but almost gompletely lack tumor-promoting activity when chronically applied to initiated mice that were not pretreated with PMA in stage I.
thesis. The inhibition of tumor formation by HU in the twostage promotion experiment did not prevent a subsequent promotion of cells by repetitive PMA treatment. This indicates that the inhibitory effect of HV was due neither to cytotoxicity (killing of initiated cells) nor to an interference with initiation. The data indicate that epidermal DNA synthesis is obligatory for PMA-induced first-stage promotion. The causal relationship between both events remains to be established, Tumor formation in mouse skin can be effected by a single application of a subthreshold dose of a carcinogen followed by repeated treatment with a noncarcinogenic tumor promoter (for review, see refs. 1 and 2). The mechanism by which the promoter converts initiated but phenotypically apparently normal cells into visible tumors is not understood.
An induction of hyperproliferation and perhaps inflammation are probably necessary, but certainly not sufficient, conditions of promotion because irritant skip mitogens have been described (3) (4) (5) that are highly effective in these respects but almost completely lack promoting capacity. Therefore, a tumor promoter must have an additional activity. Most of the biochemical responses of mouse skin to application of promoters such as phorbol ester PMA (phorbol 12-myristate 13-acetate) analyzed so far seem to be related to hyperproliferation and inflammation (3, 6) but do not shed light on the nature of the particular mechanisms involved in promotion. Recently, skin tumor promotion has been found to consist of two different stages (3, 7, 8) . Whereas for stage I a single (i.e., subthreshold) application of a promoter such as PMA is sufficient, stage II is performed by continuous treatment with an "incomplete" promoter (3, 7) . Incomplete promoters such as phorbol 12-tetradeca-2,4,6,8-tetraenoate 13-acetate (Ti8) and phorbol 12-retinoate 13-acetate (PRA) (3, 6) exhibit hyperplasiogenic and irritant activities like those of PMA but almost gompletely lack tumor-promoting activity when chronically applied to initiated mice that were not pretreated with PMA in stage I.
For stage II of skin tumor promotion, a long-term stimulation of epidermal cell proliferation resulting in a sustained hyperplasia (9) seems to be an obligatory and perhaps sufficient condition. Thus, the hyperplasiogenic activity of a "complete" tumor promoter may reflect its stage Il-promoting activity. On the other hand, the induction of epidermal hyperproliferation also could be necessary for stage I. Cell culture studies have shown that replicating cells may indeed be more sensitive to "complete" than to "incomplete" phorbol ester tumor promoters. In HeLa cells, which have no target for the mitogenic capacity, PMA exerts distinct effects on cell-cycle traverse, which are Similar to those seen after x-irradiation (10) (11) (12) . These include a delay in DNA synthesis, which was shown to be due to inhibition of replicon initiation rather than replicon elongation (13) . "Incomplete" promoters are significantly less active in evoking this radiomimetic response (14) . It might be possible, therefore, that the stage I-promoting activity of PMA depends on cell proliferation or even resides in a particular interaction with replicating epidermal cells.
To address this problem, we asked whether a temporary inhibition by hydroxyurea (HU) of DNA replication would alter tumor promotion during stage I. The results indicate that the stimulation of DNA-synthesis in epidermal cells is necessary for the first stage of skin tumor promotion.
MATERIALS AND METHODS
Materials. The phorbol ester PMA was a generous gift from E. Hecker (German Cancer Research Center). PRA was prepared as reported (15 (16) and is swiftly metabolized and excreted (17, 18) . The dose applied was in the plateau region of the dose-response curve for the inhibitory activity on-mouse epidermal DNA synthesis (16) and is supposedly not toxic under the conditions of this study (19, 20 (21) .
DNA Labeling. DNA synthesis in mouse epidermis in vivo was determined by pulse-labeling with [3H]thymidine and isolation of labeled DNA as described (22) . For determination of the epidermal labeling jndex, mice were injected i.p. with 2.0 /uCi of [methyl-3H]thymidine per g of body weight. After 1 hr, the animals were killed by cervical dislocation. The back skin was immediately dissected off and fixed in 10% formalin; 5-pkm sections were covered with Kodak nuclear track emulsion. After 10 days, the film was developed, and the sections were stained with hematoxylin/eosin. Nuclei with more than five silver grains per nucleus were counted as labeled.
RESULTS
Initiation by intragastric administration of DMBA (50 Mg/g) to NMRI mice and two-stage promotion by a single application of PMA (20 nmol) followed by repeated treatment with PRA (10 nmol) resulted in -95% tumor incidence and six to seven papillomas per animal within 18 weeks ( Fig. 1 and Table 1). Without PMA (i.e., after chronic PRA treatment alone), only 22% incidence and a tumor yield of 0.6-1.1 tumors per surviving mouse were reached (Table 1) . These values of the PMA/PRA group versus the PRA control determine the range within which a modulation of tumor formation was to be expected.
To test the effect of HU on stage I of promotion, we injected the inhibitor i.p. either 1 hr prior to or 6, 12, 18, 24, or 48 hr after PMA application. Under these conditions tumor formation was increasingly depressed, with maximal inhibition when HU was given 18 hr after PMA (Table 1 and Fig. 2 ). At this time point, tumor formation was reduced almost to the level of the PRA control (Fig. 1) . HU given either 1 showing a first maximum after 18 hr. To demonstrate this relation, the labeling curve has been included in Fig. 2 . Under the conditions of the experiment, the 18-hr peak of DNA labeling was indeed found to be inhibited by HU treatment (Fig. 3) .
To rule out the possibility that HU diminishes tumor formation by killing initiated cells instead of by inhibiting promotion, we continued the experiments shown in Fig. 1 (Fig. 4) Mice were treated with either 0.1 ml of acetone (hatched area) or a solution of 20 nmol of PMA in 0.1 ml of acetone and were killed at the times indicated. Labeled thymidine (1 ,uCi/g of body weight) either with or without HU (0.5 mg/g of body weight) was dissolved in 0.3 ml of 0.9% NaCl and injected i.p. 1 hr prior to sacrifice. Specific radioactivity of epidermal DNA was determined as described (20) . Each experimental point represents the mean SD. The acetone-treated control is indicated by the horizonal lines (n = 12) o, PMA/HU treatment; e, PMA/NaCl treatment.
when HU was applied once 18 hr after the first PMA application, when tumor promotion was carried out in the classical manner by means of chronic PMA treatment twice weekly (Fig. 5) .
DISCUSSION
A single dose of HU has been found to diminish skin tumorigenesis when applied in combination with PMA during stage I of promotion. Maximal inhibition was observed when the drug was given at the time of maximal DNA synthesis-i.e., 18 hr after PMA treatment. This indicates that the antitumorigenic effect of HU is a direct consequence of the drug's antiproliferative activity. HU is known to inhibit DNA synthesis by interfering with the enzyme ribonucleotide reductase, which catalyzes the formation of deoxyribonucleotides (for review, see ref. 23 ). In mammalian cells the effect of small concentrations of HU is considered to be reversible (23 (27) . An (30) . Since a hyperplastic response of mouse epidermis is also provoked by agents that do not exhibit stage I-promoting activity, it has to be concluded that the induction of epidermal hyperproliferation is a necessary but not sufficient condition of stage I of tumor promotion. The same may be proposed to be true for certain secondary phenomena of the hyperplastic response, such as the induction of prostaglandin synthesis, ornithine decarboxylase activity, and hormone refractoriness (31) .
The precise role of cellular proliferation in stage I of promotion is not known. Tentatively, two explanations may be offered.
(i) Stage I of promotion has been postulated to involve an expression of the tumor phenotype. For such a process, cellular proliferation could have a "helper function" as has been shown for the differentiation of certain cell lineages (32) . This would mean that "quantal cell division" (32) is required to express the functional program of neoplastic development determined by initiation.
(it) Another hypothesis is based on observations made on PMA-treated HeLa cell cultures. Here the phorbol ester has been found to exhibit effects on the cell cycle, including those on cells in S phase that are quite similar to those seen after irradiation (10) (11) (12) . If one makes a similar assumption for PMA-treated mouse epidermis, one would come to the conclusion that, for stage I of promotion, a specific interaction of PMA with S-phase cells is prerequisite and that HU inhibits the formation of such cells. The precise nature of such an interaction is unknown. Moreover, it has to be explained why an "incomplete" tumor promoter such as PRA would be less potent to interact with S-phase cells (14) . 
